Multicenter Validation of a 1,550-Gene Expression Profile for Identification of Tumor Tissue of Origin

University of Pittsburgh, Pittsburgh, Pennsylvania, United States
Journal of Clinical Oncology (Impact Factor: 17.88). 04/2009; 27(15):2503-8. DOI: 10.1200/JCO.2008.17.9762
Source: PubMed

ABSTRACT Malignancies found in unexpected locations or with poorly differentiated morphologies can pose a significant challenge for tissue of origin determination. Current histologic and imaging techniques fail to yield definitive identification of the tissue of origin in a significant number of cases. The aim of this study was to validate a predefined 1,550-gene expression profile for this purpose.
Four institutions processed 547 frozen specimens representing 15 tissues of origin using oligonucleotide microarrays. Half of the specimens were metastatic tumors, with the remainder being poorly differentiated and undifferentiated primary cancers chosen to resemble those that present as a clinical challenge.
In this blinded multicenter validation study the 1,550-gene expression profile was highly informative in tissue determination. The study found overall sensitivity (positive percent agreement with reference diagnosis) of 87.8% (95% CI, 84.7% to 90.4%) and overall specificity (negative percent agreement with reference diagnosis) of 99.4% (95% CI, 98.3% to 99.9%). Performance within the subgroup of metastatic tumors (n = 258) was found to be slightly lower than that of the poorly differentiated and undifferentiated primary tumor subgroup, 84.5% and 90.7%, respectively (P = .04). Differences between individual laboratories were not statistically significant.
This study represents the first adequately sized, multicenter validation of a gene-expression profile for tissue of origin determination restricted to poorly differentiated and undifferentiated primary cancers and metastatic tumors. These results indicate that this profile should be a valuable addition or alternative to currently available diagnostic methods for the evaluation of uncertain primary cancers.

Download full-text


Available from: Maureen Lyons, Jul 03, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In this paper, analysis of the finite wordlength effects for the implementation of a digital neural networks adaptive tracking controller and the update law of the weight matrices for a class of nonlinear system is proposed. Both the quantization and computational errors are considered. In the sense of the Lyapunov stability, weight matrices of the neural networks and the error between the identified states and real system states will converge during finite time interval. Moreover, a robust stability condition can be obtained in terms of the mantissa bit number. Based on this criterion, the existence of the controller can be guaranteed
    Neural Networks, 2002. IJCNN '02. Proceedings of the 2002 International Joint Conference on; 02/2002
  • [Show abstract] [Hide abstract]
    ABSTRACT: The measurement method of EMI radiated from information technology equipment (ITE) above 1 GHz has been discussed in CISPR. The authors think that further discussions are necessary of EUT size, measurement distance, receiving antenna beamwidth, material of EUT table, etc. In this paper, we describe the influence of EUT size and receiving antenna beamwidth upon the measurement results.
    Electromagnetic Compatibility, 2002. EMC 2002. IEEE International Symposium on; 09/2002
  • [Show abstract] [Hide abstract]
    ABSTRACT: Pathologists use various panels of immunohistochemical (IHC) stains to identify the site of tissue of origin for metastatic tumors, particularly poorly or undifferentiated cancers of unknown or uncertain origin. Although clinicians believe that immunostains contribute greatly to determining the probable primary site among 3 or more possibilities, objective evidence has not been convincingly presented. This meta-analysis reviews the objective evidence supporting this practice and summarizes the performance reported in 5 studies published between 1993 and 2007. A literature search was conducted to identify IHC performance studies published since 1990 that were masked, included more than 3 tissues types, and used more than 50 specimens. The 5 studies found in this search were separated into 2 subgroups for analysis: those, which included only metastatic tumors (n = 368 specimens) and the blended studies, which combined primary tumors and metastases (n = 289 specimens). The meta-analysis found that IHCs provided the correct tissue identification for 82.3% (95% confidence interval = 77.4%-86.3%) of the blended primary and metastatic samples and 65.6% (95% confidence interval = 60.1%-70.7%) of metastatic cancers. This difference is both clinically and statistically significant. This literature review confirms that there is still an unmet medical need in identification of the primary site of metastatic tumors. It establishes minimum performance requirements for any new diagnostic test intended to aid the pathologist and oncologist in tissue of origin determination.
    Applied immunohistochemistry & molecular morphology: AIMM / official publication of the Society for Applied Immunohistochemistry 07/2009; 18(1):3-8. DOI:10.1097/PAI.0b013e3181a75e6d · 2.06 Impact Factor